申请人:MERCK & CO. INC.
公开号:EP0497524A2
公开(公告)日:1992-08-05
Type-specific capsular polysaccharide preparations from Streptococcus pneumoniae, having on average less than about 1000 oligosaccharide repeat units per molecule, polydispersities between 1.0 and 1.4, intrinsic viscosities between 0.6 and 3.0 dL/g, and less than 3% contamination of type-specific polysaccharide by group-specific C-polysaccharide, are produced by a novel process. The novel type specific polysaccharide products are useful in the preparation of vaccines, especially covalent conjugates comprising the novel polysaccharide linked to a T-cell stimulatory carrier protein. Vaccines comprising the novel polysaccharides are useful in the prevention of infection and of diseases associated with infection by Streptococcus pneumoniae.
肺炎链球菌的型特异性荚膜多糖制剂是通过一种新工艺生产的,平均每个分子中的寡糖重复单位少于约 1000 个,多分散度在 1.0 到 1.4 之间,固有粘度在 0.6 到 3.0 dL/g 之间,型特异性多糖被群体特异性 C 多糖污染的程度低于 3%。新型特异性多糖产品可用于制备疫苗,特别是由新型多糖与刺激 T 细胞的载体蛋白连接而成的共价结合物。由新型多糖组成的疫苗可用于预防肺炎链球菌感染以及与肺炎链球菌感染相关的疾病。